Trial Profile
Study of FK949E - An Open-label, Two-way Crossover Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 May 2017
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Bipolar I disorders; Bipolar II disorders; Major depressive disorder
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 22 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Feb 2015 New trial record